Antifungals in Clinical Use and the Pipeline

Rezafungin: a novel antifungal for the treatment of invasive candidiasis

(2021) Young Yoon Ham et al.   Future Microbiology

Mechanisms of acquired in vivo and in vitro resistance to voriconazole by Candida krusei following exposure to suboptimal drug concentration

(2020) Elisabete Ricardo et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Lipid Systems for the Delivery of Amphotericin B in Antifungal Therapy

(2020) Faustino et al.   Pharmaceutics

Pharmacokinetics and Pharmacodynamics of Posaconazole

(2020) Lu Chen et al.   DRUGS

Molecular mechanisms of posaconazole- and itraconazole-induced pseudohyperaldosteronism and assessment of other systemically used azole antifungals

(2020) Katharina R. Beck et al.   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma

(2020) Jannik Stemler et al.   ANNALS OF HEMATOLOGY

Caspofungin weight-based dosing supported by a population pharmacokinetic model in critically ill patients

(2020) Anne-Grete Märtson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Safety and tolerability of a novel oral formulation of amphotericin B: Phase I EnACT Trial

(2020) Caleb Skipper et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Population pharmacokinetics of caspofungin among extracorporeal membrane oxygenation (ECMO) patients during the postoperative period of lung transplantation(LTx)

(2020) Qianlin Wang et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antifungal therapeutic drug monitoring: focus on drugs without a clear recommendation

(2020) A. Gómez-López   CLINICAL MICROBIOLOGY AND INFECTION

Oral Ibrexafungerp: an investigational agent for the treatment of vulvovaginal candidiasis

(2020) Nkechi Azie et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Isavuconazole therapeutic drug monitoring during long-term treatment for chronic pulmonary aspergillosis

(2020) Chris Kosmidis et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Rezafungin versus Caspofungin in a Phase 2, Randomized, Double-Blind Study for the Treatment of Candidemia and Invasive Candidiasis- The STRIVE Trial

(2020) George R Thompson et al.   CLINICAL INFECTIOUS DISEASES

Maternal use of fluconazole and congenital malformations in the progeny: A meta-analysis of the literature

(2020) Maria Cristina Budani et al.   REPRODUCTIVE TOXICOLOGY

Twenty Years of the SENTRY Antifungal Surveillance Program: Results for Candida Species From 1997–2016

(2019) Michael A Pfaller et al.   Open Forum Infectious Diseases

The Development of Oral Amphotericin B to Treat Systemic Fungal and Parasitic Infections: Has the Myth Been Finally Realized?

(2019) Grace Cuddihy et al.   Pharmaceutics

Aerosolized Lipid Amphotericin B for Complementary Therapy and/or Secondary Prophylaxis in Patients with Invasive Pulmonary Aspergillosis: A Single-Center Experience

(2019) E. Venanzi et al.   MYCOPATHOLOGIA

In vitro activity of APX001A against rare moulds using EUCAST and CLSI methodologies

(2019) Olga Rivero-Menendez et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Associations between low- and high-dose oral fluconazole and pregnancy outcomes: 3 nested case–control studies

(2019) Anick Bérard et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

APX001 Pharmacokinetic/Pharmacodynamic Target Determination against Aspergillus fumigatus in an In Vivo Model of Invasive Pulmonary Aspergillosis

(2019) Miao Zhao et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Adverse Effects Associated with Long-Term Administration of Azole Antifungal Agents

(2019) Lydia L. Benitez et al.   DRUGS

Efficacy of Oral Encochleated Amphotericin B in a Mouse Model of Cryptococcal Meningoencephalitis

(2019) R. Lu et al.   mBio

ESCMID-ECMM guideline: diagnosis and management of invasive aspergillosis in neonates and children

(2019) A. Warris et al.   CLINICAL MICROBIOLOGY AND INFECTION

Prevalence of voriconazole-resistant invasive aspergillosis and its impact on mortality in haematology patients

(2019) Agustin Resendiz-Sharpe et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis

(2019) Andrej Spec et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Antifungal drugs: What brings the future?

(2019) Ruth Van Daele et al.   MEDICAL MYCOLOGY

Isavuconazole Diffusion in Infected Human Brain

(2019) Claire Rouzaud et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Posaconazole Serum Drug Levels Associated with Pseudohyperaldosteronism

(2019) Minh-Vu H Nguyen et al.   CLINICAL INFECTIOUS DISEASES

Fetal outcomes after maternal exposure to oral antifungal agents during pregnancy: A systematic review and meta‐analysis

(2019) Dan Liu et al.   INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS

Long-term risk of hepatocellular carcinoma mortality in 23220 hospitalized patients treated with micafungin or other parenteral antifungals

(2019) Sebastian Schneeweiss et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Review on Antifungal Resistance Mechanisms in the Emerging Pathogen Candida auris

(2019) Farid Chaabane et al.   Frontiers in Microbiology

Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium

(2019) Oliver A Cornely et al.   LANCET INFECTIOUS DISEASES

Lack of Effect of Rezafungin on QT/QTc Interval in Healthy Subjects

(2019) Shawn Flanagan et al.   Clinical Pharmacology in Drug Development

A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of orally administered VT-1161 in the treatment of recurrent vulvovaginal candidiasis

(2018) Stephen R. Brand et al.   AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY

The effect of the novel antifungal drug F901318 (Olorofim) on the growth and viability of Aspergillus fumigatus

(2018) Saskia du Pré et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

EUCAST Determination of olorofim (F901318) susceptibility of mould species, method validation and MICs

(2018) Karin Meinike Jørgensen et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics of Anidulafungin in Obese and Normal-Weight Adults

(2018) Roeland E. Wasmann et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Significantly improved pharmacokinetics enhances in vivo efficacy of APX001 against echinocandin and multidrug resistant Candida isolates in a mouse model of invasive candidiasis

(2018) Yanan Zhao et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Isavuconazole Concentration in Real-World Practice: Consistency with Results from Clinical Trials

(2018) David Andes et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline

(2018) A.J. Ullmann et al.   CLINICAL MICROBIOLOGY AND INFECTION

The antifungal arsenal: alternative drugs and future targets

(2018) Nathan P. Wiederhold   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Caspofungin dosage adjustments are not required for patients with Child–Pugh B or C cirrhosis

(2018) Thierry Gustot et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

OUP accepted manuscript

(2018)   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Lack of Impact by SCY-078, a First-in-Class Oral Fungicidal Glucan Synthase Inhibitor, on the Pharmacokinetics of Rosiglitazone, a Substrate for CYP450 2C8, Supports the Low Risk for Clinically Relevant Metabolic Drug-Drug Interactions

(2018) Stephen Wring et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Isavuconazole shortens the QTc interval

(2018) Sibylle C. Mellinghoff et al.   MYCOSES

In Vivo Efficacy of VT-1129 against Experimental Cryptococcal Meningitis with the Use of a Loading Dose-Maintenance Dose Administration Strategy

(2018) Nathan P. Wiederhold et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Responding to the emergence of antifungal drug resistance: perspectives from the bench and the bedside

(2018) Justin Beardsley et al.   Future Microbiology

Voriconazole exposure and risk of cutaneous squamous cell carcinoma among lung or hematopoietic cell transplant patients: A systematic review and meta-analysis

(2018) Huilin Tang et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Voriconazole Resistance and Mortality in Invasive Aspergillosis: A Multicenter Retrospective Cohort Study

(2018) Pieter P Lestrade et al.   CLINICAL INFECTIOUS DISEASES

Pharmacokinetics and probability of target attainment for micafungin in normal-weight and morbidly obese adults

(2018) Roeland E Wasmann et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Fungal-specific Cyp51 inhibitor VT-1598 demonstrates in vitro activity against Candida and Cryptococcus species, endemic fungi, including Coccidioides species, Aspergillus species and Rhizopus arrhizus

(2017) Nathan P Wiederhold et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Pharmacodynamics of the Orotomides against Aspergillus fumigatus : New Opportunities for Treatment of Multidrug-Resistant Fungal Disease

(2017) William W. Hope et al.   mBio

Phase 1 Study to Assess Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of APX001 and to Investigate the Effect of Food on APX001 Bioavailability

(2017) Michael R Hodges et al.   Open Forum Infectious Diseases

Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi

(2016) Amit Desai et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Drug-Drug Interaction Associated with Mold-Active Triazoles among Hospitalized Patients

(2016) David Andes et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Aspergillus fumigatus Intrinsic Fluconazole Resistance Is Due to the Naturally Occurring T301I Substitution in Cyp51Ap

(2016) Florencia Leonardelli et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Safety and Pharmacokinetics of CD101 IV, a Novel Echinocandin, in Healthy Adults

(2016) Taylor Sandison et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Fungal CYP51 Inhibitors VT-1161 and VT-1129 Exhibit Strong In Vitro Activity against Candida glabrata and C. krusei Isolates Clinically Resistant to Azole and Echinocandin Antifungal Compounds

(2016) W. A. Schell et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis

(2016) John N. Galgiani et al.   CLINICAL INFECTIOUS DISEASES

Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America

(2016) Thomas F. Patterson et al.   CLINICAL INFECTIOUS DISEASES

Chromoblastomycosis

(2016) Flavio Queiroz-Telles et al.   CLINICAL MICROBIOLOGY REVIEWS

Antifungal Agents

(2016) Jeniel E. Nett et al.   INFECTIOUS DISEASE CLINICS OF NORTH AMERICA

Association Between Use of Oral Fluconazole During Pregnancy and Risk of Spontaneous Abortion and Stillbirth

(2016) Ditte Mølgaard-Nielsen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Short-term risk of liver and renal injury in hospitalized patients using micafungin: a multicentre cohort study

(2016) Sebastian Schneeweiss et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis

(2016) Haiying Jin et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Therapeutic drug monitoring and safety of intravenous voriconazole formulated with sulfobutylether β-cyclodextrin in haematological patients with renal impairment

(2016) Si-Hyun Kim et al.   MYCOSES

Efficacy and safety of amphotericin B lipid-based formulations-A systematic review and meta-analysis

(2016) Laiza M. Steimbach et al.   MYCOSES

Pharmacokinetics and Safety of Micafungin in Infants Supported With Extracorporeal Membrane Oxygenation

(2016) Julie Autmizguine et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase

(2016) Jason D. Oliver et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Brain, Amphotericin B, and P-Glycoprotein

(2015) David A. Stevens et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy of the Clinical Agent VT-1161 against Fluconazole-Sensitive and -Resistant Candida albicans in a Murine Model of Vaginal Candidiasis

(2015) E. P. Garvey et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacodynamics of Amphotericin B Deoxycholate, Amphotericin B Lipid Complex, and Liposomal Amphotericin B against Aspergillus fumigatus

(2015) Zaid Al-Nakeeb et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Population Pharmacokinetic Modeling of Itraconazole and Hydroxyitraconazole for Oral SUBA-Itraconazole and Sporanox Capsule Formulations in Healthy Subjects in Fed and Fasted States

(2015) Ahmad Y. Abuhelwa et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antifungal Activities of SCY-078 (MK-3118) and Standard Antifungal Agents against Clinical Non-Aspergillus Mold Isolates

(2015) Frédéric Lamoth et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America

(2015) Peter G. Pappas et al.   CLINICAL INFECTIOUS DISEASES

Worsening renal function in patients with baseline renal impairment treated with intravenous voriconazole: A systematic review

(2015) R. Brigg Turner et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent

(2015) Jeffrey M. Rybak et al.   PHARMACOTHERAPY

The Clinical Candidate VT-1161 Is a Highly Potent Inhibitor of Candida albicans CYP51 but Fails To Bind the Human Enzyme

(2014) A. G. S. Warrilow et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroandIn VivoEvidence for Amphotericin B as a P-Glycoprotein Substrate on the Blood-Brain Barrier

(2014) Ji-Qin Wu et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Contribution of Clinically Derived Mutations inERG11to Azole Resistance in Candida albicans

(2014) Stephanie A. Flowers et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others

(2014) A.M. Tortorano et al.   CLINICAL MICROBIOLOGY AND INFECTION

ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi

(2014) A. Chowdhary et al.   CLINICAL MICROBIOLOGY AND INFECTION

Tissue Penetration of Antifungal Agents

(2014) T. Felton et al.   CLINICAL MICROBIOLOGY REVIEWS

CYP2C19Polymorphisms and Therapeutic Drug Monitoring of Voriconazole: Are We Ready for Clinical Implementation of Pharmacogenomics?

(2014) Aniwaa Owusu Obeng et al.   PHARMACOTHERAPY

Antifungal Pharmacokinetics and Pharmacodynamics

(2014) A. J. Lepak et al.   Cold Spring Harbor Perspectives in Medicine

Weight Drives Caspofungin Pharmacokinetic Variability in Overweight and Obese People: Fractal Power Signatures beyond Two-Thirds or Three-Fourths

(2013) Ronald G. Hall et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Increasing Echinocandin Resistance in Candida glabrata: Clinical Failure Correlates With Presence of FKS Mutations and Elevated Minimum Inhibitory Concentrations

(2013) Barbara D. Alexander et al.   CLINICAL INFECTIOUS DISEASES

Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme

(2013) M.C. Arendrup et al.   CLINICAL MICROBIOLOGY AND INFECTION

Amphotericin B Formulations: A Comparative Review of Efficacy and Toxicity

(2013) Richard J. Hamill   DRUGS

Itraconazole: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections

(2013) Jodi Lestner et al.   Expert Opinion on Drug Metabolism & Toxicology

An elevated pro-inflammatory cytokine response is linked to development of amphotericin B-induced nephrotoxicity

(2013) L. Y. A. Chai et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

A Quantitative Analysis of the Spontaneous Reporting of Congestive Heart Failure-Related Adverse Events With Systemic Anti-Fungal Drugs

(2013) Manfred Hauben et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Aerosolized Amphotericin B Lipid Complex as Adjunctive Treatment for Fungal Lung Infection in Patients with Cancer-Related Immunosuppression and Recipients of Hematopoietic Stem Cell Transplantation

(2013) Amar Safdar et al.   PHARMACOTHERAPY

Voriconazole Serum Concentrations in Obese and Overweight Immunocompromised Patients: A Retrospective Review

(2013) Samantha Davies-Vorbrodt et al.   PHARMACOTHERAPY

Successful Use of Posaconazole for Treatment of Blastomycosis

(2012) Laurie A. Proia et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The Presence of anFKSMutation Rather than MIC Is an Independent Risk Factor for Failure of Echinocandin Therapy among Patients with Invasive Candidiasis Due to Candida glabrata

(2012) Ryan K. Shields et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Administration of Voriconazole in Patients With Renal Dysfunction

(2012) D. Neofytos et al.   CLINICAL INFECTIOUS DISEASES

ESCMID* *This guideline was presented in part at ECCMID 2011. European Society for Clinical Microbiology and Infectious Diseases. guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp.

(2012) W.W. Hope et al.   CLINICAL MICROBIOLOGY AND INFECTION

Evaluation of the effect of obesity on voriconazole serum concentrations

(2012) E. Koselke et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America

(2010) John R. Perfect et al.   CLINICAL INFECTIOUS DISEASES

Review of the Basic and Clinical Pharmacology of Sulfobutylether-β-Cydodextrin (SBECD)

(2010) David R. Luke et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Review of the pharmacology and clinical studies of micafungin

(2010) Alison Bormann   Drug Design Development and Therapy

Possible Environmental Origin of Resistance of Aspergillus fumigatus to Medical Triazoles

(2009) E. Snelders et al.   APPLIED AND ENVIRONMENTAL MICROBIOLOGY

Clinical Relevance of the Pharmacokinetic Interactions of Azole Antifungal Drugs with Other Coadministered Agents

(2009) Roger J. M. Brüggemann et al.   CLINICAL INFECTIOUS DISEASES

Pharmacokinetics of caspofungin and voriconazole in critically ill patients during extracorporeal membrane oxygenation

(2009) I. Spriet et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Drug-Drug Interaction Study of Ketoconazole and Ritonavir-Boosted Saquinavir

(2008) B. Kaeser et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics and Absorption of Posaconazole Oral Suspension under Various Gastric Conditions in Healthy Volunteers

(2008) G. Krishna et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antifungal Therapeutic Drug Monitoring: Established and Emerging Indications

(2008) D. Andes et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical Practice Guidelines for the Management of Blastomycosis: 2008 Update by the Infectious Diseases Society of America

(2008) Stanley W. Chapman et al.   CLINICAL INFECTIOUS DISEASES

Current Options in Antifungal Pharmacotherapy

(2008) John Mohr et al.   PHARMACOTHERAPY

Cyclodextrins

(2008) Valentino J. Stella et al.   TOXICOLOGIC PATHOLOGY

Voriconazole Therapeutic Drug Monitoring in Patients with Invasive Mycoses Improves Efficacy and Safety Outcomes

(2007) A. Pascual et al.   CLINICAL INFECTIOUS DISEASES